Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : APLS save search
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-04 (Crawled : 20:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.8%
H: 0.85%
C: 0.56%
nasdaq pharmaceuticals grants
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 1.4%
H: 2.13%
C: 1.79%
conference pharmaceuticals
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.28%
H: 2.62%
C: -1.25%
retina medical
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.89%
H: 1.78%
C: 1.56%
nasdaq pharmaceuticals grants
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -3.03%
H: 1.84%
C: -0.3%
year pharmaceuticals financial results
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.47%
H: 4.52%
C: 4.27%
pharmaceuticals
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -1.03%
H: 2.54%
C: -0.32%
conference year pharmaceuticals financial results
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.09%
H: 0.07%
C: -0.82%
nasdaq pharmaceuticals grants
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Published: 2024-01-26 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.35%
H: 0.41%
C: -3.0%
chmp application negative
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.42%
H: 16.66%
C: 15.14%
year
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-05 (Crawled : 21:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
| Email alert
Add to watchlist
nasdaq pharmaceuticals grants
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.05%
H: 2.97%
C: 2.3%
conference pharmaceuticals
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas
Published: 2023-12-28 (Crawled : 20:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.37%
H: 1.25%
C: -4.38%
management
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
Published: 2023-12-28 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.06%
H: 2.54%
C: -0.11%
conference pharmaceuticals
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -15.28%
H: 0.05%
C: -2.05%
review update ongoing
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Published: 2023-12-11 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -1.29%
H: 0.15%
C: -3.29%
empaveli control meeting
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-06 (Crawled : 21:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 1.62%
H: 2.3%
C: 0.06%
nasdaq pharmaceuticals grants
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-21 (Crawled : 12:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.77%
H: 2.18%
C: 0.49%
conference pharmaceuticals
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 1.34%
H: 3.67%
C: 2.69%
nasdaq pharmaceuticals grants
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
Published: 2023-11-04 (Crawled : 20:20) - globenewswire.com
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
| Email alert
Add to watchlist
syfovre treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.